Clinical Trial Update: SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating SHR-1210 plus apatinib in advanced hepatocellular carcinoma is reported, with status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Apatinib (apatinib)
• SHR-1210 (camrelizumab)

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN